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One prominent and distinguishing feature of progressive, age-related neurological
diseases such as Alzheimer’s disease (AD) and prion disease (PrD) is the gradual
accumulation of amyloids into dense, insoluble end-stage protein aggregates. These
polymorphic proteolipid lesions are known to contribute to immunogenic and
inflammatory pathology in these insidious and fatal disorders of the human central
nervous system (CNS). For example, the evolution of self-aggregating amyloid-beta
(Aβ) peptides, such as the 42 amino acid Aβ42 peptide monomer into higher order
aggregates are largely due to: (1) the inability of natural processes to clear them from
the cellular environment; and/or (2) the overproduction of these amyloid monomers
which rapidly mature into higher order oligomers, fibrils and insoluble, end-stage
senile plaques. Cells of the CNS such as microglial (MG) cells have evolved essential
homeostatic mechanisms to clear Aβ peptides to avoid their accumulation, however,
when defective, these clearance mechanisms become overwhelmed and excessive
deposition and aggregation of these amyloids result. This ‘Perspectives’ paper will
highlight some emerging concepts on the up-regulation of an inducible microRNA-34a
in AD and PrD that drives the down-regulation of the amyloid sensing- and clearance
receptor protein TREM2 (the triggering receptor expressed in myeloid/microglial
cells). The impairment of this inducible, miRNA-34a-regulated TREM2- and MG-
cell based amyloid clearance mechanism may thereby contribute to the age-related
amyloidogenesis associated with both AD and PrD.
Keywords: 42 amino acid amyloid-beta (Aβ42) peptides, Alzheimer’s disease (AD), Creutzfeldt-Jakob
disease (CJD), Gerstmann-Straussler-Scheinker syndrome (GSS), microglial cells, microRNA-34a, phagocytosis,
triggering receptor expressed in myeloid/microglial cells (TREM2)
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OVERVIEW AND CURRENT STATUS OF
mIRNA EXPRESSION IN AD AND PrD
Recent miRNA array-, Northern-, quantitative RT-PCR,
and/or RNA-sequencing-based analyses have uncovered a
small group of inducible, pathogenic microRNAs (miRNAs)
significantly up-regulated in degenerating central nervous
system (CNS) tissues, and these appear to be involved in the
coordinate down-regulation of disease-relevant messenger
RNA (mRNA) targets (Sethi and Lukiw, 2009; Guo et al., 2010;
Lukiw et al., 2011; Yaghmoor et al., 2014; Zhao et al., 2015a,b;
Bhattacharjee et al., 2016; Clement et al., 2016; University of
California San Francisco [UCSF], 2016). This small family of
up-regulated miRNAs include miRNA-9, miRNA-34a, miRNA-
125b, miRNA-146a, and miRNA-155; for example their 1.7-
to 5.8-fold up-regulation in AD neocortex targets a set of
degeneration-relevant mRNAs involved in the regulation of
gliosis, glial cell proliferation, the innate-immune response,
inflammatory signaling, deficits in neurotrophic signaling,
synaptogenesis, and amyloidogenesis. One prominent Aβ42
peptide and related amyloid clearance pathway affected
in neurodegenerative processes in the CNS appears to be
an inducible miRNA-34a-regulated TREM2 mRNA circuit
(Lukiw et al., 2011; Zhao et al., 2013; Boese et al., 2015; Zhao
et al., 2015a; Zhu et al., 2015; Song et al., 2016; Ulrich and
Holtzman, 2016). Briefly, TREM2, the triggering receptor
expressed in myeloid/microglial cells and encoded by a ∼2700
nucleotide (nt) mRNA at chr 6p21.1, yields a ∼26 kDa (230
amino acid) variably glycosylated type 1 transmembrane
glycoprotein of the immunoglobulin gene superfamily highly
expressed in MG cells, the ‘resident immune cells’ of the
CNS. As a rather recently recognized myeloid/microglial
cell surface amyloid sensor-receptor, TREM2 appears to
play a critical function in innate-immune surveillance, the
sensing of amyloid and phagocytosis throughout the CNS,
including the recognition and ingestion of neurotoxic Aβ42
peptides and related extracellular amyloidogenic debris
(Zhu et al., 2015; Song et al., 2016; Ulrich and Holtzman,
2016). The TREM2 mRNA 3′-untranslated region (3′-UTR;
299 nt) contains an unusually strong recognition feature
for miRNA-34a; the energy of association (EA) between
hsa-miRNA-34a (encoded at chr 1p36.15) and the TREM2
mRNA-3′UTR sequence is ∼16.2 kcal/mol; hence gene
products on chromosome 1 and 6 orchestrate a biologically
relevant TREM2 expression that impacts phagocytosis
(Zhu et al., 2015; Song et al., 2016; Ulrich and Holtzman,
2016). TREM2 signaling is in part mediated through a MG
membrane-associated tyrosine kinase-binding protein/DNAX
activation adaptor protein of 12 kDa (TYROBP/DAP12),
however, no deficit in TYROBP/DAP12 in AD or PrD has
yet been identified, and we cannot exclude deficiencies in
other phagocytic proteins at the present time (Yaghmoor
et al., 2014; Zhu et al., 2015). On the other hand significant
TREM2 deficits have been reported during inflammatory
neurodegeneration of the human CNS including sporadic
AD and age-related macular degeneration (AMD; Zhao et al.,
2013; Zhu et al., 2015; Bhattacharjee et al., 2016; Song et al.,
2016). It is not clear what role TREM2 plays in amyloidogenic
processes associated with prion infected human brain in
Creutzfeldt-Jakob disease (CJD) or Gerstmann-Straussler-
Scheinker (GSS), although markers of MG activation are
down-regulated in prion-infected TREM2-/- mice suggesting
TREM2 involvement in prion-induced MG-activation (Song
et al., 2016; Ulrich and Holtzman, 2016). In this brief report,
we for the first time provide data on the up-regulation of
these five inducible miRNAs, and prominently miRNA-
34a, in two rare human prion diseases: the transmissible
spongiform encephalopathies (TSE) sporadic CJD (incidence
∼1 per million) and GSS syndrome (incidence ∼1–10 per
100 million), and compare them to their levels in sporadic
AD (Lukiw et al., 2011; Yaghmoor et al., 2014). We further
provide evidence that wild type MG cells can effectively
phagocytose Aβ42 peptides while miRNA-34a-treated MG
cells (compared to scrambled miRNA-treated controls) exhibit
both a significantly attenuated TREM2 signal and a reduced
ability to ingest and clear Aβ42 peptide from the extracellular
space. Using miRNA array-based analytical approaches,
recent findings further indicate that miRNA-9, miRNA-34a,
miRNA-125b, miRNA-146a, and miRNA-155 exhibit similar
up-regulation in sporadic AD and in PrD brain (Table 1),
TABLE 1 | Relative expression of AD-relevant miRNAs in the prion diseases sJCD and Gerstmann-Straussler-Scheinker (GSS) indicate a similar
up-regulation of these inducible, NF-kB-regulated miRNAs; clinical parameters including age and gender of these human PrD cases (both JCD and GSS)
have been described in detail elsewhere (Lukiw et al., 2011).
Control AD sCJD GSS Fold increase AD/control Fold increase CJD/control Fold increase GSS/control
N 9 12 3 2 − − −
miRNA-9-5p 15657 38661 48529 46969 2.5 3.1 3
miRNA-34a-5p 261 1176 1410 1875 4.5 5.4 7.2
miRNA-125b-5p 15310 26424 32150 35213 1.7 2.1 2.3
miRNA-146a-5p 304 1756 1915 2463 5.8 6.3 8.1
miRNA-155-5p 370 968 1182 1222 2.6 3.2 3.3
Numbers under Control, Alzheimer’s disease (AD), sCJD or GSS are the means of each sample’s miRNA signal as indicated; briefly the average ages of sCJD (n = 3)
and the controls (n = 6) were 66 ± 8 years and the mean ages of the GSS (n = 2) and controls (n = 6) were 61 years; there were no significant differences in total RNA
yield or purity between any AD or control, or prion-affected brain samples (Lukiw et al., 2011; Zhao and Lukiw, 2015; Bhattacharjee et al., 2016); due to their extreme
rarity and limited availability, only sCJD and GSS small RNAs, and no brain tissue protein extracts were available for the current investigation; in AD, sCJD, and GSS
miRNA-34a exhibited one of the highest up-regulations ranging from 4.5- to 7.2-fold over relevant controls.
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FIGURE 1 | TREM-2 mediated phagocytosis of Aβ42 peptides in murine microglial (MG) cells - control or a scrambled-miRNA-34a
(+miRNA-34a-sc)-treated MG cells efficiently phagocytose Aβ42 peptides; miRNA-34a-treated MG cells do not; (A) C8B4 MG cells (ATCC CRL-2540)
cultured for 3 days (control) were treated with 5 µM of Aβ42 peptides (American Peptide Company, Sunnyvale, CA, cat # 62-0-80A) for 24 h before
staining; briefly, Aβ42 peptide was completely dissolved in hexafluoroisopropanol (HFIP; Fluka Chemical, cat# 52512; Sigma–Aldrich, St. Louis, MO), lyophilized and
stored at −20◦C; HFIP films were re-suspended to 5 mM with DMSO then diluted to 5 µM and introduced into C8B4 MG culture medium (Stine et al., 2003; Yanagi
et al., 2011; Bhattacharjee et al., 2016); cells were incubated with either a scrambled miRNA-34a sequence (+miRNA-34a-sc) (B) or with a locked nucleic acid
(LNA) protected miRNA-34a (+miRNA-34a) (C) (each at 30 nM); treatments were for 24 h before incubation with 5 uM of Aβ42 peptides for another 24 h before
assay; MG cells were subsequently stained with (a) a murine amyloid beta MABN10 (red fluorescence λmax∼650 nm; anti-Aβ antibody, clone W0-2; Millipore,
Billerica, MA); (b) a TREM-2 antibody (M-227; sc-48765; green fluorescence; λmax∼510 nm; Santa Cruz, CA); or (c) a DAPI nuclear stain (blue fluorescence;
λmax∼470 nm); (d) represents a merged view of all three fluorescent stains; we note a decreased TREM2 presence in miRNA-34a treated MG cells (bottom row,
panel b) and a consistent decrease in ingested Aβ42 peptides within C8B4 MG cells (C); bottom row, panel (d) magnification 20×. These and previous results
together indicate a miRNA-34a-mediated down-regulation of TREM2 and an inability to ingest Aβ42 peptide from the surrounding medium; note (i) the rapid
self-aggregation of Aβ42 peptides into ‘clumps’; (ii) affinity of Aβ42 peptides for TREM2 containing MG cells (leftmost panels); and (iii) internalization of Aβ42
peptides (yellow merge; λmax∼580 nm; rightmost panels); Aβ42 peptide analysis and quantification was performed using SlideBook 5.0 (Intelligent Imaging
Innovations) and ImageJ (NIH) software; under control conditions approximately 40–45% of Aβ42 peptides were cleared from the extracellular medium after 24 h;
this was reduced to less than 8% in miRNA-34a treated MG cells. These results are consistent with other recent reports of an elevated miRNA-34a down-regulating
TREM2 expression in MG cells, and defective miRNA-34a-TREM2-mediated signaling pathways in cellular models of inflammatory neurodegeneration (Zhao et al.,
2013; Hickman and El Khoury, 2014; Bhattacharjee et al., 2016; Ulrich and Holtzman, 2016).
that miRNA-34a induces a deficiency in the expression of
MG cell TREM2, and a defect in the ability of MG cells to
phagocytose (Figure 1; Zhao and Lukiw, 2015; Bhattacharjee
et al., 2016).
CONCLUDING REMARKS
Our understanding of the highly specialized functions for
small, ∼18–25 nt non-coding RNAs such as miRNAs in the
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CNS continues to evolve, and their abundance and patterns
of expression underscore our recognition of the complexity
of miRNA-mRNA-mediated genetic regulatory networks in the
human CNS in health and disease (Lukiw, 2007; Schipper et al.,
2007; Cogswell et al., 2008; Boese et al., 2015; Zhao and Lukiw,
2015; Zhu et al., 2015; Basak et al., 2016). While the importance
small non-coding RNAs in human CNS neurodegeneration
including AD have been recognized for at least a quarter
century (Lukiw et al., 1992), specific pathogenic miRNAs, their
expression patterns, regulatory actions and their participation in
development, aging and diseases of the CNS are all relatively
new discoveries within the last decade. Indeed, it has almost
been 10 years since the first description of selective miRNA
alterations in AD brain and in related neurological conditions
(Lukiw, 2007; Premzl and Gamulin, 2007; Schipper et al., 2007;
Cogswell et al., 2008; Smit-McBride et al., 2014; Hill et al.,
2015; Boese et al., 2015; Zhao and Lukiw, 2015; Zhu et al.,
2015; Basak et al., 2016). One truly remarkable finding is
that a significant up-regulation of inducible, pro-inflammatory
pathogenic miRNAs such as miRNA-34a and/or miRNA-146a
are shared by AD (Hill and Lukiw, 2015; Hill et al., 2015; Zhao
et al., 2015a,b; Basak et al., 2016), PrD and murine scrapie
in the CNS (Lukiw et al., 2011; Boese et al., 2015) and in
aging and AMD of the human retina (Smit-McBride et al.,
2014; Hill et al., 2015; Bhattacharjee et al., 2016; data not
shown). Common patterns of miRNA abundance, speciation
and/or complexity in the degenerating brain and retina are
particularly interesting because: (i) both the brain and retina
are commonly derived during development from the neural
ectoderm; (ii) both brain and retina exhibit basic alterations
in the innate-immune response, inflammatory signaling and
amyloid generation and clearance during neurodegeneration
(such as seen in AD, PrD and AMD); and (iii) dys-homeostasis
of beta-amyloid precursor protein (βAPP) and amyloid-beta
(Aβ) peptides generated from βAPP and their associated βAPP
cleavage enzymes (PS1, α-secretase, β-secretase) and βAPP-
docking and membrane-associated proteins (such as TSPAN12
and caveolin-1) confined to βAPP-enriched lipid raft domains
accompany both age-related brain and retinal degeneration
(AD, AMD, PrD; Hill et al., 2015; Zhao and Lukiw, 2015;
Basak et al., 2016; Bhattacharjee et al., 2016). It is therefore
tempting to speculate and our evolving opinion: (i) that a
specific subfamily of pathogenic, CNS-abundant miRNAs (such
as miRNA-34a and miRNA-146a) appear to be involved in
common amyloidogenic aspects of selective forms of brain and
retinal inflammatory neurodegeneration; (ii) that commonly
altered mechanisms of βAPP, Aβ42, prion amyloids, other forms
of amyloid and/or amyloid-derived fragment generation and
clearance appear to be integral to the onset, pathogenesis and/or
propagation of CNS diseases with a progressive amyloidogenic
component; (iii) that poorly understood mechanisms of core
pathogenic processes involving the homeostatic balance between
pro-inflammatory miRNA signaling and the generation and
clearance of Aβ42- and/or prion-based amyloids are a common
unifying feature of AD and PrD; and (iv) that a more in
depth knowledge of selective molecular-genetic components
of these amyloidogenic mechanisms and pro-inflammatory
pathways should provide additional targets for pharmacological
intervention and the more effective clinical management of these
enigmatic neurodegenerative proteinopathies (Tousseyn et al.,
2015; Falker et al., 2016).
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